SRR26320082
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.430
- G2M_CHECKPOINT+0.340
- PROTEIN_SECRETION+0.330
- ANDROGEN_RESPONSE+0.290
- E2F_TARGETS+0.280
- MITOTIC_SPINDLE+0.220
- TGF_BETA_SIGNALING+0.200
- SPERMATOGENESIS+0.190
- MTORC1_SIGNALING+0.150
- ANGIOGENESIS+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- MYOGENESIS-0.360
- BILE_ACID_METABOLISM-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- APICAL_SURFACE-0.320
- INFLAMMATORY_RESPONSE-0.290
- XENOBIOTIC_METABOLISM-0.290
- IL6_JAK_STAT3_SIGNALING-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- COAGULATION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.846 |
| 2 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.836 |
| 3 | SJEPD030795_D3.RNA-Seq | EPN | Posterior Fossa EPN | 0.832 |
| 4 | SRR3147744 | — | — | 0.832 |
| 5 | ERR2598198 | fetal | fetal | 0.816 |
| 6 | TCGA-A8-A07C-01A-11R-A034-07 | — | E | 0.815 |
| 7 | ERR2598089 | fetal | fetal | 0.813 |
| 8 | MDT-AP-3311 | Med | Medulloblastoma | 0.812 |
| 9 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.812 |
| 10 | SJEPD031786_D2.RNA-Seq | EPN | Anaplastic EPN | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |